Concepedia

James R. Porter

JR

Statistics

Publications

10

Citations

972

H-Index

10

Active since

2003

Affiliations

Infinity Pharmaceuticals (United States)(Current)

Memorial Sloan Kettering Cancer Center

Wellesley College

Sarah Cannon

University of Colorado Anschutz Medical Campus

James R. Porter is an author at Infinity Pharmaceuticals (United States) specializing in pharmacology, medicine, and cancer pharmacology.

ORCID

Publications per year

2003–2024

10

Publications

10

PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models

David G. Winkler, Jonathan P. DiNitto, Janid A. Ali et al. · Chemistry & Biology · 2013 · 258 citations

, , +15

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90

Jens Sydor, Emmanuel Normant, Christine Pien et al. · Proceedings of the National Academy of Sciences · 2006 · 227 citations · Full text

, , +13

Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90

Jie Ge, Emmanuel Normant, James R. Porter et al. · Journal of Medicinal Chemistry · 2006 · 189 citations · Full text

, , +10

Semisynthetic Cyclopamine Analogues as Potent and Orally Bioavailable Hedgehog Pathway Antagonists

Martin Tremblay, Marta Nevalainen, Somarajan Nair et al. · Journal of Medicinal Chemistry · 2008 · 107 citations

, , +13

NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations

Alexander Drilon, Joshua C. Horan, Anupong Tangpeerachaikul et al. · Cancer Discovery · 2022 · 49 citations · Full text

, , +15

1–5 of 10